e As a follow-up of the "spoligoriftyping" development, we present here an extension of this technique which includes the detection of isoniazid resistance-associated mutations in a new 59-plex assay, i.e., tuberculosis-spoligo-rifampin-isoniazid typing (TB-SPRINT), running on microbead-based multiplexed systems. This assay improves the synergy between clinical microbiology and epidemiology by providing (i) mutation-based prediction of drug resistance profiles for patient treatment and (ii) genotyping data for tuberculosis (TB) surveillance. This third-generation microbead-based high-throughput assay for TB runs on the Luminex 200 system and on the recently launched MagPix system (Luminex, Austin, TX). Spoligotyping patterns obtained by the TB-SPRINT method were 100% (n ‫؍‬ 85 isolates; 3,655/3,655 spoligotype data points) concordant with those obtained by microbead-based and membrane-based spoligotyping. Genetic drug susceptibility typing provided by the TB-SPRINT method was 100% concordant with resistance locus sequencing (n ‫؍‬ 162 for rpoB gene sequencing and n ‫؍‬ 76 for katG and inhA sequencing). Considering phenotypic drug susceptibility testing (DST) as the reference method, the sensitivity and specificity of TB-SPRINT regarding Mycobacterium tuberculosis complex (n ‫؍‬ 162 isolates) rifampin resistance were both 100%, and those for isoniazid resistance were 90.4% (95% confidence interval, 85 to 95%) and 100%, respectively. Used routinely in national TB reference and specialized laboratories, the TB-SPRINT assay should simultaneously improve personalized medicine and epidemiological surveillance of multidrug-resistant (MDR) TB. This assay is expected to play an emerging role in public health in countries with heavy burdens of MDR TB and/or HIV/TB coinfection. Application of this assay directly to biological samples, as well as development for extensively drug-resistant (XDR) TB detection by inclusion of second-line antituberculosis drug-associated mutations, is under development. With bioinformatical methods and data mining to reduce the number of targets to the most informative ones, locally adapted formats of this technique can easily be developed everywhere.
T uberculosis (TB) remains an international health problem, and many efforts have been made to control the disease since it was declared a global emergency 20 years ago (1) . Multidrugresistant (MDR) TB prevalence is increasing, accounting for 3.7% of new cases worldwide and 20% of previously treated cases (2) . The steady increases in MDR TB and extensively drug-resistant (XDR) TB are associated with changes in the selective pressure exerted against TB (3, 4) . In countries where laboratory capacities to perform diagnostic tests for XDR TB are available, at least one case of XDR TB was identified microbiologically (2) . The majority (85%) of drug-susceptible, MDR, and XDR TB cases occur in resource-limited countries (Asian and African regions). In 2011, 58% of incident TB cases (8.7 million estimated) occurred in China, India, Indonesia, South Africa, and Pakistan, and 60% of MDR TB cases occurred in Brazil, China, India, the Russian Federation, and South Africa (2) . Moreover, these countries have alarming economic (poverty), social (malnutrition), and health (HIV infection) situations, which are promoting factors for TB (2) . Immigration exposes countries with lower TB prevalence to strains of Mycobacterium tuberculosis that are MDR or XDR, from countries with large disease burdens and subefficient TB control programs (5) .
Although the Xpert MTB/RIF assay is a remarkable innovation and the assay price reduction could accelerate its uptake, we still need cost-effective, robust methods for early subspecies identification/detection of M. tuberculosis and simultaneous detection of resistance to all antituberculosis drugs. A molecular diagnostic assay that not only allows personalized treatment but also contributes to reducing MDR/XDR TB transmission and improving epidemiological surveillance would be of considerable interest.
Molecular mechanisms of Mycobacterium tuberculosis complex (MTC) drug resistance are well known and are reported to involve mutations in specific genes. Rifampin (RIF) resistance involves mutations in the rpoB gene (the 81-bp rifampin resistance-determining region [RRDR] ), and isoniazid (INH) resistance is associated with mutations in katG (codon 315), inhA (positions Ϫ15 and Ϫ8 in the inhA promoter sequence), and other genes (6) (7) (8) (9) (10) (11) (12) . Our knowledge of the genetic basis of MTC drug resistance and the use of nucleic acid amplification tests (NAATs) have allowed development of commercial PCR-based tests for resistance detection, such as the INNO-LiPA Rif-TB, Genotype MTBDRplus, and Xpert MTB/RIF assays (13) (14) (15) . Other research and diagnostic methods have been developed, although DNA sequencing remains the standard (16, 17) .
Microbead-based DNA chip systems, using either flow cytometry or fluorescence imaging, theoretically allow targeting of up to 500 markers in the same tube. These technologies have gained wide acceptance for tissue typing and immunology (18) . Their use for infectious disease control is expanding, even in low-resource countries (19) . In parallel, the theoretical power of clustered regularly interspersed short palindromic repeats (CRISPR)-based genotyping techniques looks promising for new bacterial models (20, 21) .
We previously reported on the development of spoligoriftyping, a method that combines spoligotyping and rifoligotyping (22) (23) (24) . We now extend the method to the detection of INH resistance-associated mutations within katG and inhA genes. To perform this, we included in our assay katG and inhA gene mutation markers that had been targeted in the rifampin-isoniazid oligonucleotide typing (RIOT) study (17) and adapted the assay to a microbead-based format. To provide a 50-target test for MagPix (Luminex, Austin, TX), we identified the most significant spacers using the knowledge discovery in databases (KDD) process. The goal of this new study was to develop and to validate a highthroughput assay to achieve simultaneous MTC characterization at the subspecies level by spoligotyping and detection of drug resistance mutations. The test was successfully developed for firstline drugs and can be applied to crude DNA extracts from cultures. Work focused on improving sensitivity with DNA extracted from clinical samples is in progress.
MATERIALS AND METHODS
Multiplex analyzers. We used two Luminex high-throughput systems, i.e., the flow cytometry-based Luminex 200 system and the MagPix fluorescent imager (Luminex Corp., Austin, TX). Oligonucleotide-precoupled MicroPlex and MagPlex beads (polystyrene and magnetic microbeads, respectively) prepared in-house were used throughout the study. These reagents (research use only) are available from the genotyping public platform within our institute (Institute of Genetics and Microbiology, Orsay, France).
Patient isolates and DNA extraction. A total of 163 DNA samples extracted by the cetyltrimethylammonium bromide (CTAB) method from MTC isolates (n ϭ 163) obtained by culture on Löwenstein-Jensen solid medium and/or liquid Middlebrook 7H9 modified broth medium, in the MGIT 960 TB system (BD Biosciences, Piscataway, NJ), were used for this study (25) . A total of 162 isolates had been tested with phenotypic drug susceptibility testing (DST) for RIF and INH using either the Bactec MGIT 960 TB system or the proportion method (26) .
These DNA samples (n ϭ 163) each corresponded to a unique TB patient. Seventy-six samples were from the CorpoGen DNA bank and were kindly provided by Patricia Del Portillo (CorpoGen Corp., Bogotá, Colombia). Their profiles were 20 susceptible, 55 RIF and/or INH resistant, and 1 unknown. These DNA samples belonged to TB patients originating from nine countries (see Tables S1 and S3 in the supplemental material). The remaining 87 samples (all MDR TB) were from patients living in Bulgaria and were kindly provided by Stefan Panaiotov and Elisabeta Bachiivska (National Center of Infectious and Parasitic Diseases and National TB Laboratory, Sofia, Bulgaria); this set was used previously for spoligoriftyping development. All DNA samples were tested individually with the new tuberculosis-spoligo-rifampin-isoniazid typing (TB-SPRINT) method on the two Luminex consoles.
Oligonucleotides, capture probes, PCR, and analysis. We designed two pairs of dual-priming oligonucleotide (DPO) primers to simultaneously amplify 180-bp fragments of the katG gene (overlapping the codon 315 position) and the inhA promoter (overlapping the Ϫ15 and Ϫ8 positions) within the multiplex PCR previously described (22) . All the primers used are shown in Table 1 ; they include probes/primers previously described for high-throughput spoligotyping (27) , spoligoriftyping (22) , and the RIOT method (17) , as well as in this study. In total, 43 probes were used for spoligotyping, 10 probes for rpoB hot-spot direct and indirect mutation detection, and 6 probes for the katG and inhA genes (katG codon 315 and InhA positions Ϫ15 and Ϫ8) (17, 22, 28) .
The PCRs and PCR product hybridization have been described previously (22) . The protocol for the MagPix is the same as that for the Luminex 200 except that the use of magnetic beads is mandatory. The minimal numbers of microbeads used by the analyte are 1,800 to 2,000 for polystyrene or magnetic beads in the Luminex 200 system and 1,200 for magnetic beads in the MagPix system. Since the MagPix allows detection of only 50 analytes, we suggest running a full TB-SPRINT experiment on the MagPix system with two separate hybridization assays, one using the spoligotyping microbeads (43-plex format) and one using the rpoB-katGinhA microbeads (16-plex format), or using the format described here. Use of the Luminex 200 system provides a full "all-in-one assay" service.
Principle, interpretation of values, statistics, and cutoffs. The principle for interpreting TB-SPRINT raw values is the same as described previously (22) . Cutoff values were established statistically for all markers in the Luminex 200 and MagPix systems (see Table S2 in the supplemental material). We specifically used a set of strains (n ϭ 75) with both sequencing and TB-SPRINT raw results to calculate the six katG and inhA probe cutoffs. We also used a set of strains (n ϭ 50) with reference method results (sequencing or membrane-based and/or high-throughput spoligotyping patterns) and Luminex 200 and MagPix raw data to calculate the cutoff values for the 43 spacer probes and 10 rpoB probes for both systems (see Table S2 in the supplemental material). A script previously developed with R software (http://www.r-project.org) was applied for statistical calculations. Once the cutoff values were determined, the raw values for all samples were automatically compared with the cutoff values in order to determine the presence (positive) or absence (negative) of the corresponding sequences, and the status (wild-type/mutated) of the singlenucleotide polymorphism (SNP) was automatically inferred by comparing the results obtained for the probes (comparison of mutant and wild-type findings and comparison with cutoff values). Briefly, two cutoffs are calculated for each marker, i.e., a positive cutoff, above which the marker is interpreted as positive (present), and a negative cutoff, below which the marker is interpreted as negative (absent). Between the two cutoffs is an indeterminate zone, in which less than 2% of values (with the Luminex 200 system) may fall. In addition, the wild-type/mutated allele status for drug resistance genes is easily determined with internal controls (wild-type/mutant ratio), which facilitates interpretation of the numerical results with in-house-created Excel (Microsoft) macros that assist automated interpretation (see Tables S1 and S3 in the supplemental material).
Sequencing data. To validate mutation detection by the TB-SPRINT method, we used sequencing results. Sequencing data for the rpoB, katG, and inhA genes were already available for some clinical isolates previously used in the spoligoriftyping or RIOT studies; other isolates were newly sequenced. The rpoB gene (411-bp fragment length), katG gene (835-bp fragment length), and inhA gene (532-bp fragment length) were sequenced for 16 strains with three pairs of primers, either already described or newly designed (Table 1) . Sequencing was subcontracted (Beckman Coulter Genomics, Grenoble, France) and was performed with the Sanger method. In total, 162 DNAs were sequenced in the rpoB gene hot-spot region and 76 DNAs were sequenced in the katG and inhA resistancedetermining regions. Membrane-based spoligotyping results were also available for 85 DNAs from Bulgarian isolates and had been checked by high-throughput spoligotyping.
RESULTS

Cutoff determination.
To determine when relative fluorescence intensity (RFI) values should be considered positive or negative, we used reference samples. We also set a maximum value for negatives and a minimum value for positives for every marker for Luminex 200 and MagPix (see Table S2 in the supplemental material). As expected, these cutoffs were highly correlated between the two methods (for minimal positive values, r ϭ 0.69, t ϭ 5.2 [df ϭ 31], P Ͻ 0.001; for maximal negative values, r ϭ 0.87, t ϭ 10.0 [df ϭ 31], P Ͻ 0.001). For the interpretation of raw values, when wild-type and mutant probes were available for a given position (e.g., codon 531 in rpoB), the raw values were compared first with their respective cutoffs and then with each other (wild-type/ mutant).
Spoligotyping patterns and genetic diversity of MTC strains. We obtained spoligotyping patterns for all 163 isolates included in this study. The spoligotyping patterns were 100% concordant with those obtained previously by membrane-based reverse lineblotting or by the previously described spoligoriftyping method for the same isolates (n ϭ 85 isolates; 3,655/3,655 spoligotype data points). Of 163 clinical isolates (after comparison with an updated SpolDB4 database), 44 (30%) belonged to the T1 lineage (n ϭ 29 for SIT53), 39 (24%) belonged to the Turkish lineage (Tur for SIT41), 15 belonged to the Haarlem lineage (Haarlem 1 to 3), 11 belonged to the Beijing clade (SIT1), and the other lineages were underrepresented, as shown in Fig. 1 .
Sequencing and TB-SPRINT mutation detection. Of the 162 isolates that were sequenced to look for rpoB mutations, 105 had the codon 531 TCG/TTG mutation, 27 had the wild-type allele, 5 had the codon 531 TCG/TGG mutation, 5 had the codon 526 CAC/GAC mutation, 3 had the codon 526 CAC/TAC mutation, 7 had the codon 516 GAC/GTC mutation, and the rest carried another mutation or double mutations. The predominant mutation conferring RIF resistance was the codon 531 TCG/TTG mutation, which was found in 80% of the resistant isolates (105/135 mutant isolates). Certain rpoB mutations were detected indirectly with the Spa_wt1 and Spa_wt2 probes and were confirmed by sequencing (Table 2; see also Tables S1 and S3 in the supplemental material).
The katG and inhA genes of 76 isolates were also sequenced to detect isoniazid resistance mutations. For the katG gene, the wildtype allele (n ϭ 34), the codon 315 AGC/ACC mutation (n ϭ 40, among which 6 isolates had double katG and inhA mutations), This study a 5=-Biotinylated; all other spoligotyping probes are as described previously (27) . b Contains a 5=-amino-C 12 linker.
and the codon 315 AGC/AAC mutation (n ϭ 2) were observed. For the inhA gene, the wild-type allele (n ϭ 64) and the position Ϫ15 C¡T mutation (n ϭ 12, including the 6 strains with double mutations) were observed ( Table 2; see also Table S1 in the supplemental material). When we compared the TB-SPRINT method with sequencing, we obtained 100% concordance (Table 3) . Correlation of phenotypic DST with TB-SPRINT. The 162 clinical isolates from which DNA had been extracted were tested phenotypically for RIF and INH resistance (Table 3) . For RIF, 100% concordance with TB-SPRINT results was found; 136 isolates were classified as resistant and 26 as susceptible by both methods. For INH, some of the resistant isolates were not detected by the TB-SPRINT method, as the method currently does not target all resistance loci; 135 isolates were resistant and 27 were susceptible by phenotypic DST, whereas 122 isolates were resistant and 40 were susceptible by the TB-SPRINT method (see Table  S3 in the supplemental material). Hence, there were some phenotypically INH-resistant isolates (n ϭ 13 [10%]) that lacked mutations in the selected regions.
Based on TB-SPRINT results, 45% of INH-resistant isolates (61/135 isolates) harbored the katG codon 315 AGC/ACC mutation, 36% (48/135 isolates) harbored the inhA position Ϫ15 C¡T mutation, and 5% (7/135 isolates) carried double mutations at Sensitivity and specificity of TB-SPRINT versus phenotypic DST and sequencing. When we compared the TB-SPRINT method with phenotypic DST, the sensitivity and specificity were 100% for RIF, keeping in mind that 95% of mutations are found in the hot spot. For INH testing, however, the sensitivity and specificity were 90.4% (95% confidence interval, 85 to 95%) and 100%, respectively (Table 3) .
Data mining results and preliminary results on optimization of a fourth-generation test. We used an in-house database of spoligotyping patterns (n ϭ 2,945 from a previous study) (J. Aze, C. Sola, F. Lafosse-Marin, K. Kremer, D. van Soolingen, and G. Refrégier, unpublished data), with highly diverse MTC lineages and sublineages, to perform an extraction of knowledge on Sipina (http://eric.univ-lyon2.fr/~ricco/sipina_download.html). The goal was to perform decision tree analysis to select the most informative spacers to classify MTC strains in a maximal number of preidentified spoligo-lineages (in this case, 17 lineages, among which results are shown for 14 [Haarlem, LAM, CAS, T, Beijing, EAI, Cam, Ural, Tur, S, Mycobacterium bovis, Mycobacterium africanum-West African 1, M. africanum-West African 2, and X] in Fig. 2) (29) . Such a process remains "under construction" because of regular inclusion of new signatures, i.e., the recent description of the new lineage 7 in Ethiopia (30) . Sipina allowed us to reduce the spacer number to 18 instead of 43 (Sp2, Sp3, Sp8, Sp9, Sp10, Sp11, Sp17, Sp18, Sp19, Sp22, Sp25, Sp26, Sp28, Sp31, Sp32, Sp34, Sp39, and Sp40) to classify MTC strains into these 14 lineages (Haarlem, LAM, CAS, T, Beijing, EAI, Cam, Ural, Tur, S, M. bovis, M. africanum-West African 1, M. africanum-West African 2, and X) (Fig. 2) . These preliminary results are reported herein pedagogically to show that the development of locally specifically adapted 50-plex assays for the MagPix format, combining both drug resistance testing and spoligotyping, is feasible using previously established bioinformatical methods applied to knowledge regarding local genetic diversity. This format fits with a 50-plex MagPix assay that would provide an all-in one assay for both subtyping and predictive genetic typing.
DISCUSSION
We successfully extended the spoligoriftyping method to the detection of INH resistance mutations in the katG (mainly the codon 315 AGC/ACC mutation) and inhA (mainly the position Ϫ15 C¡T mutation) genes. The full TB-SPRINT method can be used as an all-in-one assay with the Luminex 200 system and in two steps with the MagPix system. Future developments should focus on locally optimized 50-plex assays based on data mining and target/bead number optimization to fit with the MagPix system.
In this study, the majority of RIF-resistant isolates carried a codon 531 resistance mutation in the rpoB gene; 80% of isolates (105/135 isolates) harbored the codon 531 TCG/TTG mutation, with no difference between the different subsets. This proportion is concordant with previous worldwide reports (16, 31) . Similarly, the majority of INH-resistant isolates carried either the katG codon 315 mutation or the inhA position Ϫ15 presumed ribosome binding site (RBS) mutation (10) .
The frequencies of different mutations in drug resistance genes with respect to geographic origins of MTC isolates have been described exhaustively in different studies, and a specific database was created (32) . The local predominance of a specific mutation is possible; however, we need larger worldwide studies to better understand the geographical distribution of INH resistance mutations.
For the current TB-SPRINT method, we targeted the inhA position Ϫ8, inhA position Ϫ15, and katG codon 315 mutations by including newly and previously designed katG and inhA probes from the RIOT study (17) . About 50 clinical isolates were found to harbor the inhA position Ϫ15 mutation, which falls in the presumed RBS and has been shown to alter transcription of inhA and to confer resistance to INH. No inhA position Ϫ8 A mutation was detected by sequencing or by TB-SPRINT in our samples, and just a few isolates (n ϭ 4) carried the katG codon 315 AGC/AAC mutation.
Second-line drug resistance markers have been tested and successfully transferred to the microbead format (gyrA and rrs mutation assay). Results are in progress (Gomgnimbou et al., unpublished data) . Because methods developed with the Luminex 200 or MagPix system are highly flexible, local improvements are possible (33) . This flexibility will also allow us to adapt a panel of new drug resistance targets, including different markers for different regions.
The basic molecular mechanism of resistance to INH has been described since the 1990s; it is a complex mechanism, and more work is needed to discover the remaining targets for INH resistance. The goal of this study was to develop a method aimed at characterizing the most frequent INH mutations; however, a proportion of undetected INH mutations of 10% remains too large for settings with high incidences of MDR M. tuberculosis. Thus, it is now highly desirable to design and to test more oligonucleotides to detect minor INH resistance mutations.
INH is a prodrug that is activated mainly by the catalase-peroxidase KatG; the subproducts of this oxidation produce different species that can affect different enzymes involved mainly in mycolic acid synthesis (6, 10) . Although the enoyl-acyl carrier protein reductase InhA is the most described, other mechanisms and enzymes may be involved, such as the human arylamine N-acetyltransferase (NAT) polymorphism, the TB NAT that is also required for mycolic acid synthesis, the MDP1 gene, or even the loss of a sigma factor (34) (35) (36) (37) (38) . Mycobacterial NudC may also play an important role in the inactivation of INH (39) . This complex resistance mechanism explains why the sensitivity of our test remains at 90.4%.
Recent studies suggest that some rpoB mutations within the hot spot (including the position 516 target in our assay and indirectly positions 511 and 533 too) confer low-level RIF resistance. As a consequence, careful interpretation of the molecular resistance assay results is required when such mutations are found, and a search for correlation with phenotypic DST findings is mandatory. The frequency of these low-level RIF resistance mutations is low among RIF-resistant isolates, and MICs should always be measured for such isolates (16, 40, 41) . TB-SPRINT, like the Xpert MTB/RIF assay, covers about 95% of all rifampin-resistant isolates; therefore, 100% correlation with phenotypic DST results is not to be expected in routine practice. We must also mention that many NAATs currently are unable to detect heteroresistance, an important issue for the clinical efficiency of antibiotics (42) .
Since 1995, WHO has promoted the directly observed treatment of short course (DOTS) strategy and later the DOTS-Plus regimen to improve TB treatment. Very successful results have been obtained with this strategy in many countries. TB treatment starts after a positive smear test and all TB cases are treated with the same first-line drug regimen, whereas cases of treatment failure are retreated using the same therapeutic scheme. Until now, microscopy was the only test that could be performed to start standardized treatment in many countries, especially in resourcelimited areas. We may suggest future evolution of the application of the DOTS strategy using a TB detection method (microscopy or Xpert MTB/RIF assay) plus a positive TB-SPRINT finding as a diagnostic strategy (Fig. 3) . In a given population, and according to the relative frequency of susceptible TB versus MDR TB and nontuberculous mycobacteria (NTM), it might be economically interesting to introduce the TB-SPRINT test (Fig. 3) . We estimate the maximal reagent cost of the TB-SPRINT assay as $8 (€6). Such an introduction would significantly improve the cost-effectiveness of MDR TB control. This could become another diagnostic strategy in countries with high prevalence rates of MDR TB, complementary or eventually alternative to the Xpert MTB/RIF assay, since this choice could provide detailed information to facilitate clustering analysis and the eradication of MDR/XDR TB.
Compared to line-probe assays, our test is very reliable in terms of read-out. Quantification is not done for the line-probe assays. The high-throughput bead format and the cost provide potential advantages for the application of TB-SPRINT in centralized laboratories and the MagPix in smaller laboratories. Next-generation sequencing of drug-resistant mutations is an attractive and promising strategy; however, the current cost remains out of reach for low-resource countries (43) . TB-SPRINT is currently available as an assay for research use only, which will be applied for research in specialized clinical microbiology and reference laboratories. TB-SPRINT is currently designed for use with cultured isolates (probably smear-positive samples too) when TB has already been identified; thus, it is a test for resistance and subspecies identification, while the Xpert MTB/RIF assay is primarily a test for TB detection. We are now running new studies in Nigeria and Ethiopia to adapt and to extend the TB-SPRINT assay to positive Ziehl-Neelsen (ZN) slides and other clinical specimen extracts. DNA extraction from positive ZN slides allowed successful bead-based spoligotyping of 50 to 60% of the slides studied in Burkina Faso (44) .
In conclusion, we developed TB-SPRINT, a NAAT technique that provides both patient-and community-relevant medical information for TB control. TB-SPRINT spoligotyping patterns were 100% concordant with those obtained by other methods, and RIF and INH drug resistance mutations were detected with high sensitivity and specificity. This assay could play a positive role in TB control by allowing early MDR TB diagnosis, preliminary epidemiological investigations, and genetic diversity studies. High-throughput spoligotyping with the MagPix system was recently performed in Haiti, showing that such techniques are also accessible to resource-poor countries (19) .
